One step closer to influenza vaccine inclusiveness

Mayla Sgrulletti, Giorgio Ottaviano, Maria Sangerardi, Loredana Chini, Rosa Maria Dellepiane, Baldassarre Martire, Davide Montin, Caterina Rizzo, Viviana Moschese

Research output: Contribution to journalArticlepeer-review


Flu virus infection is a common cause of acute respiratory illness, with the major incidence in pediatric age, high morbidity, and mortality. The flu vaccine is recommended for all people aged ≥6 months, unless specific contraindications are present. Younger and older age, pregnancy, chronic diseases like asthma, and immunodeficiency are risk factors for severe complications following flu infection. Thus, these categories represent the target for flu vaccine strategies in most countries. Inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV) or live-attenuated influenza virus (LAIV) are currently available, with specific precautions and contraindications. We aim to resume the current indications for vaccines in the vulnerable populations to support flu vaccination inclusiveness, in anticipation of a “universal vaccine” strategy.

Original languageEnglish
Pages (from-to)69-71
Number of pages3
JournalPediatric Allergy and Immunology
Issue numberS26
Publication statusPublished - Nov 2020


  • asthma
  • children
  • immunodeficiency
  • influenza vaccine
  • pregnancy
  • universal vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'One step closer to influenza vaccine inclusiveness'. Together they form a unique fingerprint.

Cite this